Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;158(2):620-629.
doi: 10.1016/j.chest.2020.02.044. Epub 2020 Mar 14.

Derivation and Validation of a Diagnostic Prediction Tool for Interstitial Lung Disease

Janelle Vu Pugashetti  1 , Aleksander Kitich  2 , Shehabaldin Alqalyoobi  1 , Anne-Catherine Maynard-Paquette  3 , David Pritchard  4 , Julia Graham  4 , Noelle Boctor  4 , Andrea Kulinich  1 , Elyse Lafond  5 , Elena Foster  1 , Cesar Mendez  1 , Saad Choudhry  1 , Jean Chalaoui  6 , Julie Morisset  3 , Michael Kadoch  7 , Justin M Oldham  8
Affiliations

Derivation and Validation of a Diagnostic Prediction Tool for Interstitial Lung Disease

Janelle Vu Pugashetti et al. Chest. 2020 Aug.

Abstract

Background: Interstitial lung disease (ILD) results in high morbidity and health-care utilization. Diagnostic delays remain common and often occur in nonpulmonology settings. Screening for ILD in these settings has the potential to reduce diagnostic delays and improve patient outcomes.

Research question: This study sought to determine whether a pulmonary function test (PFT)-derived diagnostic prediction tool (ILD-Screen) could accurately identify incident ILD cases in patients undergoing PFT in nonpulmonology settings.

Study design and methods: Clinical and physiologic PFT variables predictive of ILD were identified by using iterative multivariable logistic regression models. ILD status was determined by using a multi-reader approach. An ILD-Screen score was generated by using final regression model coefficients, with a score ≥ 8 considered positive. ILD-Screen test performance was validated in an independent external cohort and applied prospectively to PFTs over 1 year to identify incident ILD cases at our institution.

Results: Variables comprising the ILD-Screen were age, height, total lung capacity, FEV1, diffusion capacity, and PFT indication. The ILD-Screen showed consistent test performance across cohorts, with a sensitivity of 0.79 and a specificity of 0.83 when applied prospectively. A positive ILD-Screen strongly predicted ILD (OR, 18.6; 95% CI, 9.4-36.9) and outperformed common ILD clinical features, including cough, dyspnea, lung crackles, and restrictive lung physiology. Prospective ILD-Screen application resulted in a higher proportion of patients undergoing chest CT imaging compared with a historical control cohort (74% vs 56%, respectively; P = .003), with a significantly shorter median time to chest CT imaging (5.6 vs 21.1 months; P < .001).

Interpretation: The ILD-Screen showed good test performance in predicting ILD across diverse geographic settings and when applied prospectively. Systematic ILD-Screen application has the potential to reduce diagnostic delays and facilitate earlier intervention in patients with ILD.

Keywords: idiopathic pulmonary fibrosis; interstitial lung abnormalities; interstitial lung disease; pulmonary fibrosis; screening.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consolidated Standards of Reporting Trials guidelines diagram for prospective ILD-Screen application. HRCT = high-resolution CT; ILD = interstitial lung disease; PFT = pulmonary function test.
Figure 2
Figure 2
Time to chest CT scan in ILD-Screen-positive patients. A higher proportion of prospectively screened patients underwent chest CT imaging, and over a shorter time frame, compared with a historical control cohort (P < .001). See Figure 1 legend for expansion of abbreviation.
See this image and copyright information in PMC

Comment in

References

    1. Fischer A., Kong A.M., Swigris J.J., Cole A.L., Raimundo K. All-cause healthcare costs and mortality in patients with systemic sclerosis with lung involvement. J Rheumatol. 2018;45(2):235–241. - PubMed
    1. Collard H.R., Chen S.Y., Yeh W.S. Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc. 2015;12(7):981–987. - PubMed
    1. Best A.C., Meng J., Lynch A.M. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology. 2008;246(3):935–940. - PubMed
    1. Mooney J.J., Elicker B.M., Urbania T.H. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest. 2013;144(2):586–592. - PubMed
    1. Fischer A., Brown K.K., Du Bois R.M. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640–646. - PMC - PubMed

Publication types